Impact of prolactin treatment on enhancing the cellular responses of MCF7 breast cancer cells to tamoxifen treatment Authors: Anwar Shams Published: 2024 ABSTRACT AbstractBreast cancer remains one of the most challenging diseases to treat due to its heterogeneity, propensity to recur, capacity to spread to distant vital organs, and, ultimately, patient death. Estrogen receptor-positive illness comprises the most common breast cancer subtype. Preclinical progress is hampered by the scarcity of medication-naïve estrogen receptor-positive tumour models that recapitulate metastatic development and treatment resistance. It is becoming increasingly clear that loss of differentiation and increased cellular stemness and plasticity are important causes of cancer evolution, heterogeneity, recurrence, metastasis, and treatment failure. Therefore, it has been suggested that reprogramming cancer cell differentiation could offer an effective method of reversing cancer through terminal differentiation and maturation. In this context, the hormone prolactin is well recognized for its pivotal involvement in the development of the mammary glands lobuloalveolar tissue and the terminal differentiation that drives the production of the milk protein gene and lactation. Additionally, numerous studies have examined the engagement of prolactin in breast cancer as a differentiation player that resulted in the ablation of tumour growth and progression. Here, we showed that a pre-treatment of the estrogen-positive breast cancer cell line with prolactin led to a considerable improvement in the sensitivity of this cancer cell to Tamoxifen endocrine therapy. We also showed a favourable prognostic value of prolactin receptors/estrogen receptors 1 (or alpha) co-expression on breast cancer patients outcomes, and this co-expression is highly correlated with the well-differentiated breast tumour type. Our results revealed a fruitful aspect of the effects of prolactin in improving the responses of breast cancer cells to conventional endocrine therapy. Moreover, these findings further validated the ability of prolactin as a persuader of a more differentiated and less aggressive breast cancer phenotype. Hence, it suggested a potential implication of prolactin as a therapeutic candidate.Supplementary InformationThe online version contains supplementary material available at 10.1007/s12672-024-01701-x.Keywords: Prolactin, Differentiation, Epithelial markers, Breast cancer, Tamoxifen, Sensitivity Introduction Breast cancer continues to be the predominant cancer among women, showing high mortality and morbidity rates worldwide [1, 2]. Tumor recurrence and dissemination comprise the leading causes of breast cancer-related death, for which efficient curative treatment is still sought [3]. Breast cancer can be classified into four major molecular subtypes based on their prevalence and the expression of the hormonal receptors (HR): the estrogen receptors (ER) and the progesterone receptors (PR) [4]. About 87.2% of breast cancer accounts for the hormone receptor-positive/ human epidermal growth factor receptor 2-negative (HR + /HER2−) or Luminal A subtype [4]. Additionally, the HR-/HER2- or triple-negative breast cancer (TNBC) subtype showed 13.2%, and the HR + /HER2 + or Luminal B subtype presented 12.6% [4]. Finally, the HR-/HER2 + or HER2-E (HER2-enriched) subtype accounts for 5.1% [4]. Indeed, Hormone-dependent subtypes account for 70% of human breast cancer, for which the Luminal A (HR + /HER2-) is the most common category [5]. Also, Luminal A subtype presents an age-adjusted rate of 87.2 new cases per 100,000 women, according to the 2016–2020 dataset [6]. Importantly, it has been estimated that by 2023, approximately 297,790 new breast cancer cases will be detected [7]. The creation of the mammary glands is a distinct and orchestrated process that mainly occurs after birth. Circulating ovarian steroid hormones such as estrogen play a critical role as arbitrators of ductal morphogenesis during puberty [5]. The estrogen receptors- alpha (ER-alpha or ESR1) and estrogen receptors- beta (ER-beta or ESR2) are bound and activated by estrogen to produce its effects on mammary gland development [5]. Numerous reports studying the expression patterns of estrogen receptors and gene knock-out mice models identified the ER-alpha (ESR1) as the chief estrogen receptor for mammary epithelial cell proliferation and differentiation [5, 8–10]. Although estrogen is necessary for the proper development of the mammary glands, a woman's lifetime exposure to high estrogen levels upsurges her risk of developing breast cancer [8, 9]. Indeed, the ER-alpha signalling pathway, essential for the average growth of the mammary ductal system, also contributes to the evolution and progression of HR + /HER2− breast cancers [9, 11]. In the transgenic animal models of mammary gland epithelial cells, overexpression of ER-alpha drives mammary gland tumorigeneses [12–15]. Furthermore, 70% to 80% of human breast tumours displayed abnormal expression of ER-alpha [12–15]. Therefore, the cornerstone of treatment for ER + breast cancers is targeting the ER expression with endocrine therapy (ET), which noticeably lowers the risk of disease mortality and morbidity [5, 12]. Controlling the risk of both local and distant tumour relapse is the main objective of systemic adjuvant ET for breast cancer, as it enhances long-term survival. Selective estrogen receptor modulators (SERMs), aromatase inhibitors (AIs), and ovarian suppression comprise adjuvant ET [16, 17]. For premenopausal women with ER + breast cancer, tamoxifen (TAM) is the most well-established treatment [5, 16, 17]. Tamoxifen is a selective estrogen receptor modulator that unveils positive benefits on breast cancer control and bone metabolism [5, 16, 17]. Moreover, five years of tamoxifen administration lessens the annual breast cancer death rate by 34% in patients with ER + illness regardless of age, other tumour features, or the use of chemotherapy [18, 19]. Despite these advantages, tamoxifen also displayed adverse effects because of its estrogenic activity in different tissues [5, 16, 17], and tumours often reappear as metastatic spread due to initial or acquired resistance to endocrine treatments [20]. Since 30% of ER + tumours do not respond to tamoxifen, endocrine resistance poses a significant issue in managing these individuals [21]. Around 30–50% of patients with ER + breast cancer receiving hormonal therapy acquire therapeutic resistance, necessitating further or alternative treatments to provide continued clinical benefits [11, 22]. It was reported that low expression levels of ESR1, in addition to mutations in the ER-alpha gene (ESR1), comprise the fundamental mechanisms causing anti-estrogen resistance in patients with ER + breast cancer [23–25]. Several approaches have been investigated to reinstate the endocrine sensitivity of ER + breast cancers, including the induction of cancer cell differentiation as a non-toxic therapeutic modality [26–28]. Tumour cell differentiation therapy aims to drive the less differentiated cancer stem cells (CSCs) or cancer progenitor cells into mature lineages. This decreases the ability of cells to proliferate and their tumorigenicity while upregulating specific molecular pathways that can be sensitive to the targeted therapy [29–32]. In keeping with the intricate nature of mammary gland development and differentiation, extensive in vitro and in vivo studies have shown the indispensable role of the lactogenic hormone prolactin (PRL) and its downstream signalling pathway involving prolactin receptor (PRLR/JAK2/STAT5a/b) in promoting various phases of the regular mammary differentiation program and lactation [33–35]. Nevertheless, PRL involvement in breast cancer development required further elucidation. Many studies suggested the engagement of PRL as an autocrine/paracrine factor in promoting breast tumorigeneses and cell viability in mammary epithelial cells [36–38]. Yet, translating these reports into clinical applications in treating breast cancer patients was not prosperous [39, 40]. Indeed, PRL and PRLR have been identified as indicators of good clinicopathological characteristics (tumour differentiation) and improved patient survival outcomes in studies examining large cohorts of human breast cancer cases [41–44]. Furthermore, recent studies conducted in vivo and in vitro have confirmed the antitumorigenic contribution of PRL to the evolution and progression of breast cancer [45–49]. Following a similar concept and considering all the knowledge derived from diverse perspectives on the potent differentiation role of PRL, we postulated in the current work that treating breast cancer cells MCF-7 (representative of Luminal A/HR + HER2-breast cancer subtype) with PRL would potentially induce a more differentiated phenotype feature by superior respond to TAM treatment. Consequently, this would call for a lower dose of TAM endocrine therapy, and the emergence of unpleasant side effects would be inferior. Eventually, the risk of resistance, recurrence, and metastases would also be reduced. Materials and methods Cell cultures and reagents Dr. Aliaa Al-Amoudi provided the human breast cancer cells (MCF-7) cells from King Fahad Medical Research Center/ King Abdulaziz University as described previously [50–52]. The MCF-7 cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) media (Multicell Invitrogen) supplemented by 10% fetal bovine serum (FBS) (Gibco™ Cat. # 31966021) and 1% Pen-Strep (Multicell Invitrogen). Reagents used include recombinant human prolactin (rhPRL) (250 ng/ml) used for human cell stimulation was purchased from Abcam (Cat.# ab51703) and 96-well plates (Corning #3753 and Fisher #7201216). Sulforhodamine B assays (SRB) assay Cells were treated or left untreated with PRL (250 ng/ml) for 72 h or 21 days, either in 2% FBS or 5%FBS, respectively. Following that, cells were seeded in 96-well plates (3,000 cells/well) and treated or left untreated with a dose range of tamoxifen (0–100) mM in 10% FBS DMEM for another 72 h. Tamoxifen citrate salt was purchased from Sigma-Aldrich (Prod. No. T9262). The preparation of the drug was performed following the company’s instructions. After completion of the treatment period, the cells were fixed with 10% trichloroacetic acid in complete media and stained for 30 min with 0.4% (wt/vol) SRB (Sulforhodamine B Dye content 75%, Sigma, Cat. # 230162-5G) dissolved in 1% acetic acid. Unbound dye was removed by four washes with 1% acetic acid, and protein-bound dye was extracted with a 10 mM unbuffered Tris base. For determination of absorbance at 490 nm, a spectrophotometer (micro-plate reader) was used according to the protocol. MTT assay Cells were treated or left untreated with PRL (250 ng/ml) for 72 h or 21 days, either in 2% FBS or 5%FBS, respectively. Following that, cells were seeded in 96-well plates (3,000 cells/well) and treated or left untreated with tamoxifen (0–100) mM dose range in 10% FBS DMEM for another 72 h. After completion of the treatment period, cells were incubated with 3-(4,5-dimethyl-2-thiazolyl)- 2,5-diphenyl- 2H-tetrazolium bromide dye (MTT) at 37 °C for two hours. Following the incubation, 100–200 ml of DMSO was used to dissolve the dye. A spectrophotometer was used to measure the OD at 570 nm. MTT Dye was purchased from Sigma-Aldrich (Cat. # M5655-100MG). Dimethyl sulfoxide ReagentPlus, > 99.5% (DMSO) was purchased from Sigma, Cat. # D5879-100ML. RNA extraction and qRT-PCR For 72 h, cells were starved or treated with 250 ng/ml of PRL. Next, 1 millilitre of Invitrogen TRIzol reagent (Thermo Cat. # 15596026) was used to lyse the cells. Isolation of total RNA followed the manufacturer's instructions. Nanodrop was used to measure the quantities of RNA at 260 nm. Reverse transcription was performed using 1 mg of total RNA and the iScript Reverse Transcription supermix kit (Cat. # 170–8840; Bio-Rad). PCR amplification of cDNA was monitored in real-time using the SsoAdvanced Universal SYBER Green Supermix. Cat. # 1725270 (Bio-Rad). Assessment of the effect of the PRLR / ESR1 gene expression signature on the survival of breast cancer patients by Kaplan‐Meier plots (KM‐plot) Kaplan–Meier plots were analyzed using online (KM-plotter) software (http://kmplot.com/analysis/) [53]. This tool analyses the effect of 54,675 genes on the survival outcome of patients using 10,293 cancer samples from the Affymetrix microarray data in the Gene Expression Omnibus (GEO: http://www.ncbi.nlm.nih.gov/geo/), the European Genome phenome Archive (EGA: https://ega.crg.eu/) and The Cancer Genome Atlas (TCGA: http://cancergenome.nih.gov/) databases. The co-expression of the PRLR and ESR1 gene signature may have an impact on several parameters, such as overall survival (OS), distant metastases-free survival (DMFS), and relapse-free survival (RFS), which we examined. The co-expression in all breast cancer subtypes and then inclusively in the Luminal A subtype was investigated in a sizable cohort of individuals with breast cancer (5143 tumours). The auto-select best cut-off option was used to divide the patient cohort. In all three of the investigated parameters—OS, RFS, and DMFS—10 years (120 months) is the chosen follow-up criterion. The log-rank P-values (below 0.05 were deemed significant) and the hazard ratio (HR) with 95% confidence intervals were computed. For quality assurance, biased arrays were disregarded. Using the multigene classifier option and the mean expression levels of both gene tools offered by the KM plotter, the PRLR and ESR1 gene expression signature was obtained. PRLR and ESR1 are identified by the Affymetrix IDs 227629_at and 205225_at, respectively. Data mining of GOBO It is a Gene expression-based Outcome for Breast cancer (GOBO) online database (http://co.bmc.lu.se/gobo/) [54, 55] that includes 1881 breast cancer patients. The relationship between the PRLR and ESR1 gene co-expression and the breast cancer molecular subtypes (PAM50), tumour grades, and ER status of breast cancer was plotted using this online analytic tool. Breast cancer gene‐expression MINER (MINER) The Breast Cancer Gene-Expression Miner v4.8 (bcGen- ExMiner v4.8) (http://bcgenex.ico.unicancer.fr/BC-GEM/GEM-Accueil.php?js = 1) [56] is an online dataset of 36 published genomics data (about 5696 patients). PRLR and ESR1 protein correlations were mapped in all breast cancer subtypes and in ER + and ER- specific breast cancers using the gene expression correlation analysis tool of bc-GenExMiner 3.0 (correlation module focused analysis). The biological validation of this tool was thoroughly examined and validated for several genes, as stated in bc-GenExMiner 3.0.“http://bcgenex.centregauducheau.fr/BC-GEM/GEM_Aide.php#Data_Validation”. Statistical analysis Statistical analysis was performed using GraphPad Prism 10 software using multiple unpaired student t-tests or two-way ANOVA analyses. Results were shown as mean ± SEM and P < 0.05 was considered as cut-off for significant association. Results and discussion Treatment of MCF-7 breast cancer cells with prolactin induces a more differentiated phenotype Tamoxifen, the most well-known ET, positively affects bone metabolism and breast cancer prevention [5, 16, 17]. Users of tamoxifen have a lower risk of breast cancer, both invasive and in situ carcinomas, particularly in the first five years of treatment. Moreover, prolonging the course of therapy to ten years lowers the chance of recurrences [27]. Despite these benefits, different therapeutic sensitivity levels have been noted because of breast cancer heterogeneous background [57, 58]. Consequently, resistance to hormone treatments can occur as a primary or acquired phenomenon, thus boosting the development of a metastatic disease [20]. Patients with advanced breast cancer most often die from metastatic involvement, a potentially fatal stage of the disease [20]. Therefore, in the realm of managing breast cancer, attempts have been made to increase the cellular responses to targeted therapy [58–60]. Many strategies, such as cyclin-dependent kinase 4/6 inhibitors (CDK4/6i; Palbociclib), epigenetic modulators that block histone deacetylase (HDAC), and other signal pathway inhibitors, have been proposed to restore the sensitivity to anti-estrogen treatment in breast cancer [26]. TAM-resistant breast cancer cells undergo apoptosis when HDAC inhibition and TAM are coupled in an experimental setting to reverse the ET resistance [27, 28]. Furthermore, for some cancer types, the activation of cellular differentiation has been employed as a non-toxic treatment strategy. Differentiation therapy has previously demonstrated efficacy in the treatment of hematological malignancies, and there is a growing impetus for its use in solid tumour models, including breast cancer [29, 61]. The importance of the tumour differentiation state in solid epithelial tumours has long been recognized as a critical clinical marker in predicting cancer grades and behaviours [62, 63]. It has been suggested that loss of tumour cellular differentiation and enhanced plasticity (dedifferentiation) with loss of both luminal and epithelial properties and conversely gaining of mesenchymal/migratory and stem-like traits are the causes of metastasis and recurrence in breast cancer [64–66]. Because of the significant correlation that has been observed between tumour differentiation state and cancer severity, stemness, and poor outcome, targeting tumour cell plasticity by differentiation induction therapy has been suggested as a potentially feasible strategy to reverse and diminish cancer aggressive phenotype [30, 67, 68]. As a result, differentiation induction therapy produces a less aggressive and more homogeneous population that is better responsive to conventional treatment and exhibits superior therapeutic outcomes [29]. In this respect, the critical role of the lactogenic hormone PRL through its downstream signalling cascade in promoting normal mammary development, differentiation, and lactation has been acknowledged by plentiful studies [33–35, 69]. Previous reports investigated thoroughly the engagement of PRL in directing terminal differentiation of mammary stem cell (MaSC) hierarchy. In comparison to EGF-treated mammary epithelial cells, PRL introduction was found to shift the luminal progenitor (EpCAMhigh/+/CD49fhigh/+) cells into the mature luminal (EpCAMhigh/+/CD49flow/−) cells, i.e., a more differentiated population [69]. Furthermore, in breast cancer models, the function of PRL in eliciting a differentiated phenotype has been confirmed [47, 48, 70, 71]. The expression of PRL mRNA was correlated with well-differentiated breast tumour features by lower grade, early stage, absence of lymph node involvement, and distant spread, which were associated with good patient outcomes [43, 44]. On the other hand, knockout of PRLR (the primary driver of PRL biological effects) in ER + and HER2-E breast cancer cells augmented the tumorigenic and metastatic capacities that displayed resistance to conventional therapies [45]. Accordingly, in the current study, we proposed that treating MCF-7 breast cancer cells with PRL would ultimately enhance their susceptibility to ET (TAM) by triggering a mechanism based on cellular differentiation, thereby causing the treated cells to become a more homogeneous and differentiated population. Breast cancer cells with greater differentiation capacity may respond more favourably to breast cancer treatment [72]. They do not, therefore, require higher dosages of the medication, which is frequently linked to a higher risk of side effects, resistance, relapse, and metastasis [72–74]. To begin with, we examined the effect of PRL on inducing a more differentiated phenotype of MCF-7 cells. MCF-7 cells were treated or left untreated with PRL (250 ng/ml) for 72 h. As shown in Fig. 1A, short-term treatment of PRL resulted in increased mRNA expression levels of several epithelial differentiated luminal markers as compared to the control (MCF-7/-PRL) cells, including ER-alpha (*p = 0.011), CK-18 (**p = 0.0076), CD-24 (**p = 0.0098), PRLR (***p = 0.00005), and MUC-1 (**p = 0.0010). In contrast, we did not observe significant changes in ECAD (p = 0.422), HER-2 (p = 0.085), and PR (p = 0.422) expression levels. These markers characterized the more differentiated phenotype of breast cancer cells [75, 76]. On the other hand, compared to the control group, short PRL treatment of MCF-7 cells resulted in the downregulation of the expression of some molecular markers that distinguish aggressive breast cancer behaviours, such as the epithelial-mesenchymal transition (EMT) markers, proliferation markers, and breast cancer stemness markers [77–79]. Our results revealed that following PRL treatment, significant suppression of the expression of the mesenchymal markers SNAI (**p = 0.0076), SLUG (*p = 0.013), and ZEB-1 (*p = 0.025), the proliferative marker Ki-67 (*p = 0.025), and the cancer stemness marker CD-44 (*p = 0.030) was detected as seen in Fig. 1-B & 1-C. Indeed, our findings also showed that in response to PRL stimulation, there was a relative reduction in the mRNA expression of mesenchymal markers FN1 (p = 0.214), NCAD (p = 0.138), and VIM (p = 0.353), as well as the proliferative marker PCNA (p = 0.423). Yet, the differences in the expression values between the controls and the treated cells were not statistically significant. Additionally, no significant differences were observed between the controls and the treated cells in the mRNA expression of the mesenchymal markers TWIST (p = 0.420) and ZEB-2 (p = 0.095) (Fig. 1B, C). Interestingly, our results agreed with the earlier studies that examined the role of PRL in breast tumorigenesis in both in vitro and in vivo models. Notably, Lopez-Ozuna et al. reported a significant suppression in breast cancer stem-like cell (BCSC) subpopulations CD44 + /CD24 − and ALDH + cells and a reduction in breast tumorigenesis and mesenchymal markers following the restoration and activation of PRL pathway in different breast cancer molecular subtypes [47, 48, 70]. Of note, suppression of Ki67 expression is a well-known predictive marker for measuring the potency and efficacy of ET in primary breast cancer patients [80–82]. In agreement with this fact, we gained a remarkable reduction in the Ki67 mRNA expression upon PRL stimulation of MCF-7 cells. Furthermore, PRL treatment was found to suppress tumour growth and progression and downregulate the expression of the proliferative marker Ki67 in the xenograft mouse models of TNBC and HER2-E breast cancer subtypes [47, 48, 70]. Prolactin treatment of MCF-7 breast cancer cells induced a more differentiated phenotype: MCF-7 cells were treated or left untreated with PRL (250 ng/ml) for 72 h. The mRNA expression levels of epithelial marker panel (A), EMT transcription markers panel (B), and proliferative & stemness markers panel (C) were measured using q-RT-PCR in both MCF-7/-PRL (ctrl) and MCF-7/ + PRL (tested) cells. Results are expressed as relative expression of duplicates of three independent experiments. ER-alpha (*p = 0.011), CK-18 (**p = 0.0076), CD-24 (**p = 0.0098), PRLR (***p = 0.00005), MUC-1 (**p = 0.0010), ECAD (p = 0.422), HER-2 (p = 0.085), PR (p = 0.422), SNAI (**p = 0.0076), SLUG (*p = 0.013), ZEB-1 (*p = 0.025), FN1 (p = 0.214), NCAD (p = 0.138), VIM (p = 0.353), ZEB-2 (p = 0.095), TWIST (p = 0.420), Ki-67 (*p = 0.025), CD-44 (*p = 0.030), and PCNA (p = 0.423), ns: not significant (multiple unpaired t-test) These findings suggested that breast cancer cells shifted toward a more differentiated phenotype in response to PRL treatment, exhibiting a significant increase in the expression of ER-alpha. This outcome might have eventually contributed to enhancing the sensitivity of the MCF-7 cells to TAM-ET. Appreciably, the primary predictor of possible reactions to ET, where 50% of patients with ERα-positive breast cancer respond to anti-estrogen treatment, is the expression of the estrogen receptor [12]. Moreover, the standard practice in tumour cell differentiation therapy is forcing less differentiated CSCs or cancer progenitor cells to mature into particular lineages [29]. This lowers their ability to proliferate and become tumorigenic while increasing the sensitivity of the cells to treatment by upregulating specific biochemical pathways that can be addressed therapeutically [29, 31, 83]. Breast tumours are diverse, containing more developed cancer cells and cells resembling stem cells (undifferentiated). Recent efforts are concentrated on finding treatments that move these undifferentiated breast cancer cells toward a more differentiated phenotype (more homogeneous), making them more receptive to the intended treatment, as these cells frequently resist therapy [83]. According to Prabhakaran et al., the examined breast cancer cell lines gene expression was altered by cisplatin treatment, which caused the cells to morph toward a more differentiated phenotype and boost their reactivity to targeted therapy [83]. Altogether, these current findings substantiated the differentiated role of PRL in MCF-7 cells by provoking a less aggressive phenotype, featuring the downregulation of invasive mesenchymal/proliferative/stemness markers and induction of cellular differentiation phenotype. These results also highlighted the potential implication of PRL as a differentiation-guider therapeutic agent. Treatment of MCF-7 breast cancer cells with PRL reduces cellular viability and enhances the cellular sensitivity to Tamoxifen endocrine therapy As the previous result showed a shifting of breast cancer cells to a more differentiated phenotype following PRL treatment with significant expression of ER-alpha, these findings encouraged us to examine the responses of the PRL-pretreated MCF-7 cells to TAM treatment. Indeed, the main transcription factor causing oncogenesis in HR + /HER2- breast cancer is the estrogen receptors [5, 9, 12–15]. Most ER-alpha-positive breast cancer patients respond to anti-estrogen therapy as the expression of estrogen receptors has been, historically, the principal prognosticator of possible responses to ET [5, 12]. On the contrary, low ESR1 (ER-alpha) expression was associated with reduced sensitivity to ET in ER + breast cancer cells [23–25]. As a ligand-inducible transcription factor, ER-alpha mediates estrogens' biological effects [5, 8, 9]. Previous research using estrogen receptor-knockout mice has shown that the proliferation of terminal end buds causes ductal elongation, which depends on the estrogen receptor, specifically ER-alpha signalling [10]. Therefore, in this work, following the treatment of MCF-7 cells with PRL for 72 h, the MCF-7 cells were subjected to different concentrations of TAM treatment (0–100 mM) according to protocol. The response of MCF-7 cells to TAM treatment (or the TAM toxic effect) was measured by SRB assay. This assay is used to quantify cellular viability by measuring the protein contents of the cells [84]. As shown in the Fig. 2A, the PRL pretreated MCF-7 cells exhibited better responses to the TAM-induced growth inhibitory effects in a dose-dependent manner. This effect is represented by a curve that shifts to the left. The calculated TAM IC50 moved from 21 to 18 mM, i.e., indicating a 3 mM (16.66%) reduction from the original dose, thus equivalence to 10% more reduction in cellular growth of PRL pretreated group (MCF-7/ + PRL + TAM) cells as compared to the control group with TAM treatment only (MCF-7/-PRL + TAM) cells (****p < 0.00001). Next, we were interested in examining the prolonged effect of PRL treatment on the response of MCF-7 cells to TAM treatment following similar growth conditions for 21 days. As presented in Fig. 2B, PRL pre-treated MCF-7 cells showed a significant response to TAM treatment by reducing cellular growth by up to 21% compared to the control group. Indeed, the TAM IC50 moved from 18 to 12 mM (6 mM reduction, i.e., 33.33% reduction from the original dose) with the noticeable shifting of the curve to the left (****p < 0.00001). Interestingly, for both treatment conditions (short and prolonged PRL administration), the PRL pretreated MCF-7 cells showed a significant reduction in cellular viability even in the absence of TAM treatment, as presented in Fig. 2A, B. at the point of TAM zero concentration. This growth inhibition ability was further enhanced by the addition of TAM treatment. To further validate the effect of PRL on improving the response of MCF-7 cells to TAM therapy, we used another assay to assess the cellular viability/proliferation capacity by measuring the mitochondrial metabolic activity of MCF-7 cells using the MTT assay [85]. Following the same experimental conditions for short and prolonged PRL treatment, MCF-7 cells PRL pre-treated (MCF-7/ + PRL + TAM) displayed a significant reduction in cellular viability/ proliferation capacity after exposure to TAM in comparison to their corresponding control group (MCF-7/-PRL + TAM) for both short PRL treatment (growth reduction by 11.27%, Fig. 3A) and prolonged PRL treatment (growth reduction by 16.18%, Fig. 3B), **p = 0.0089 and ****p < 0.00001, respectively. Moreover, using the MTT assay, we could recapitulate the inhibitory effect of short and prolonged PRL treatment alone on cellular viability and growth of MCF-7 cells, even without TAM effects, as shown in Fig. 3A, B. at the point of TAM zero concentration. These results indicate that PRL treatment in both conditions, short and prolonged approaches, increased the sensitivity of the breast cancer cells to the TAM-ET and suppressed cellular viability and proliferation, subsequently requiring lower doses of TAM therapy. Prolactin treatment of MCF-7 breast cancer cells enhanced the cellular responses to the Tamoxifen treatment: MCF-7 cells were treated or left untreated with PRL (250 ng/ml) for 72 h panel (A) or 21 days panel (B). This was followed by treatment with TAM with different concentrations (0–100) mM for 72 h. Response to varying doses of TAM was measured using SRB assay at the OD of 490 nm. The IC50 values of TAM after 72 h of treatment were determined in both the control (MCF-7/-PRL + TAM) and the tested (MCF-7/ + PRL + TAM) breast cancer cells. Results are expressed as a percentage of cell viability of six replicates of three independent experiments, ****p < 0.0001(two-way ANOVA), panels (A) and (B) Prolactin treatment of MCF-7 breast cancer cells reduced the cellular viability (proliferative capacity) and improved the responses to the Tamoxifen treatment: MCF-7 cells were treated or left untreated with PRL (250 ng/ml) for 72 h panel (A) or 21 days panel (B). This was followed by treatment with TAM with different concentrations (0–100) mM for 72 h. Cell viability inhibition by various doses of TAM was also measured using an MTT assay at an OD of 570 nm. Results are expressed as mean ± SEM of six replicates of three independent experiments, panels (A) and (B), **p = 0.0089 and ****p < 0.0001(two-way ANOVA), respectively Tamoxifen provides promising benefits for breast cancer management [5]. It is the gold standard treatment for ER + breast cancer patients, with a standard regimen of 20 mg/day for 5–10 years for premenopausal patients and 2–3 years for postmenopausal patients [86]. This recommendation showed a 40% reduction in the disease recurrence rate within the first ten years and an annual decline in the mortality rate by one-third [86]. As an ER modulator, TAM can induce ER-antagonistic or agonistic effects in other organs expressing ER, resulting in numerous unpleasant effects which negatively impact the patient’s quality of life [5, 86]. These adverse effects include venous thromboembolic illness, endometrial hyperplasia, vaginal bleeding, and an elevated risk of invasive endometrial cancer [21, 86]. The occurrence of the side effects is associated with non-compliance and early discontinuation of the therapy [86]. In this context, numerous studies have been conducted to evaluate whether lowering the dose of TAM could improve the toxicity profile without affecting the clinical benefits [86–92]. A large randomized controlled trial (RCT) examined the side effects of different doses of TAM (1, 2.5, 5, 10 or 20 mg daily for 6 months) on 1440 healthy women showing high-density breast tissues on mammographic examination. This trial disclosed that lower TAM doses were associated with a low toxicity profile and were tolerable, mainly in the side effects of muscle cramps and autonomic and gynecological symptoms [93]. Additionally, a lower dose of TAM reduced the chance of experiencing several adverse effects and improved the patient’s quality of life [93, 94]. Tamoxifen at lower doses may also minimize the possibility of evolving resistance, relapses, and future metastases [89, 95]. Nevertheless, the clinical efficacy of low TAM dosage compared to the standard dosage in the adjuvant setting has never been investigated in trials due to the need for a large sample size and a long duration of patient follow-up [86]. Therefore, the anti-tumour activity of low TAM doses was investigated by examining different measures reflecting its clinical efficacy in the adjuvant setting. This includes assessing the ability of low TAM doses to reduce breast cancer development, breast tissue density, and the expression of the proliferative marker Ki67 [86]. Using the standard TAM dosage (20 mg) as recommended by American Society of Clinical Oncology (ASCO) guidelines in the primary and secondary chemo preventive conditions is correlated with a one-third reduction in breast cancer occurrence [86]. Similar prevention efficacy was obtained when a lower TAM (5 mg) dose was examined in RCT [87–89]. Furthermore, in three successful observational studies, the administration of different low doses of TAM (5 mg/day, 10 mg every other day, or 20 mg per week) for 2–5 years was investigated in breast cancer patients post-surgical resection of the tumours [90–92]. As compared to the patients who did not receive TAM, all the low TAM doses (independent of the dose) showed a comparable reduction in breast cancer development (~ 30%), mainly in post-menopausal patients [90–92]. Many reports found a positive correlation between the high density of breast tissues and the risk of breast cancer development [96, 97]. As documented by mammographic results, a recommended daily dose of TAM can significantly reduce breast tissue density after one year of treatment compared to the placebo group. This finding was associated with a significant decline in the risk of breast cancer occurrence by 63% [98, 99]. Likewise, using TAM at 5 mg/day for one year decreased mammographic tissue density compared to placebo or the standard TAM regimen [100–102]. Furthermore, different reports validated the clinical efficacy of low-dose TAM by measuring the expression profile of the proliferative marker Ki67 in breast cancer patients receiving TAM treatment [103, 104]. In this regard, various doses of TAM (1, 5, 10, or 20 mg) induced potent suppression of Ki67 activity in the ER + breast cancer patients after 4 weeks of the treatment compared to the non-treated group. The anti-tumour effects were relatively comparable between the three examined doses (i.e., independent dose effects) [103, 104]. Our current finding can be justified by the differentiation effect of PRL in generating a more differentiated population featured by the downregulation of the expression of mesenchymal/stemness/proliferative markers and the upregulation of the expression of the luminal/epithelial differentiation markers. This includes the upregulation of the primary driver of HR + /HER2− breast cancer cells, ER-alpha (ESR1), as shown in Fig. 1A, thus sensitizing the cells to lower doses of TAM compared to the controls. Endocrine treatment is typically thought to be more effective against tumours expressing high ER and/or PR levels [105]. According to the St. Gallen IBCE (International Breast Cancer Ex- pert) panel and the ASCO guidelines, breast cancer with any measurable expression of ER should be classified as HR + and responsive to ET [106]. Indeed, about 70% of human breast cancers are ER + and hormone-dependent, for which the expression of ER is the crucial element to predict the reaction to ET [5]. Adjuvant tamoxifen therapy for ER + breast cancer has significantly reduced recurrence and death [107]; however, endocrine therapy does not seem to benefit ER-negative breast cancer patients [108]. Consistent with our findings, it has been reported that PRL via the JAK2-STAT5 pathway and Stat5-response elements found in each of the Esr promoters can stimulate the expression of ER, including ER-alpha (ESR1) and ER-beta (ESR2) in the mammary gland and rat corpus luteum [109]. Prolactin and estrogen promote mammary glands' growth, development, and differentiation. Human prolactin (hPRL) was genetically engineered into MCF-7 cells to generate endogenous hPRL. This increased ER-alpha levels and estrogen responsiveness in these cells, demonstrating that endogenous hPRL cross-regulates ER-alpha levels [110]. Additionally, it was discovered that PRL increased the transcripts for molecular characteristics of the luminal/alveolar subtype of human breast cancer with a higher degree of differentiation and induced the transcriptional activity of ER-alpha (ESR1) expression [71]. Of note, the MCF-7 cells showed a highly aggressive phenotype upon elimination of the PRL pathway action through knocking out of PRLR (KO-PRLR,) which was accompanied by a loss of epithelial differentiated markers, including ER-alpha expression and a high resistance to TAM therapy [45]. These reports highlight the effectiveness of PRL in boosting the expression of markers of cellular differentiation and are consistent with our current findings. Furthermore, our findings showed that differentiated breast cancer cells respond significantly better to endocrine therapy than less or de-differentiated breast cancer cells do. From this angle, breast cancer cells, MDA-MB-231 and MCF-7 cells were treated with arsenite (AsIII) and tetrandrine (Tetra). This resulted in cellular differentiation characterized by activation of ICAM-1 and downregulation of Her2/neu. Compared to the control group, the more differentiated breast cancer cells were shown to be more susceptible to PD98059, a potent MEK/ERK pathway inhibitor [32]. Additionally, combination therapy has shown promise in the treatment of patients with breast cancer. For instance, adding palbociclib to letrozole can lower the progression-free survival (PFS), disease progression, or recurrence in women with advanced ER + breast cancer [111]. Furthermore, in patients with ER + breast cancer with advanced disease resistant to both SERMs and AIs, the addition of a mTOR inhibitor (everolimus) to exemestane can enhance the PFS in comparison to everolimus alone [27, 28]. In this work, we intend to provide novel insight into the development of new therapeutic combination strategies to combat breast cancer progression; therefore, we examined the response of the PRL pre-treated MCF-7 cells to tamoxifen, the standard endocrine therapy of HR + /HER2- breast tumours. Collectively, our study provided more evidence of the power of PRL in defeating breast cancer by inducing more differentiated phenotype and thus stimulating the breast cancer cells to lower doses of TAM endocrine therapy. Furthermore, these results postulated an attractive concept for developing a less-toxic differentiation-based therapeutic approach in treating HR + /HER2− breast cancer cells. The expression level of PRLR is positively correlated with ESR1 expression in breast cancer patients It has been demonstrated that PRL stimulates the expression of ER, both ER-alpha (ESR1) and ER-beta (ESR2), via the PRLR/JAK2/STAT5 signalling pathway [71, 109, 110]. Thus, our next goal was to investigate the relationship between ESR1 expression and PRLR expression in the various breast cancer subtypes. Using a publicly available database of bcGenExMiner v4.8 [56], we performed a thorough analysis to map the correlation between PRLR and the ESR1 proteins in a large cohort of 5696 breast cancer patients to understand better the relationship between PRLR and ESR1 and their roles in breast cancer progression. As can be seen in Fig. 4A, a strongly positive correlated interaction was obtained between PRLR and the ESR1 proteins in breast cancer patients in all subtypes collectively with Pearson’s pairwise correlation value of r = 0.51, p < 0.0001. We dissected this result and found a positive correlation between PRLR and the ESR1 protein expression maintained in both ER + and ER- breast cancer patients’ samples, Fig. 4B, C, respectively with Pearson pairwise correlation value of r = 0.32, p < 0.0001 and r = 0.37, p < 0.0001, respectively. Nevertheless, the number of breast cancer patients who showed such a positive correlation is higher (3685) in ER + breast cancer samples than the number of breast cancer patients (510) who showed such a positive correlation in ER− breast cancer samples. Thus, it suggests that the expression of both PRLR and ESR1 is down-regulated in ER-breast cancer subtypes, highlighting their potential role in maintaining the epithelial differentiated phenotype. Prolactin receptor expression positively correlates with ESR1 expression in breast cancer patients: The PRLR-ESR1 interaction map shows different degrees of correlation strength by bcGenExMiner, left and middle panels. Right panel: Pearson pairwise correlation graphs show high degree of positively correlated interaction between PRLR and ESR1 genes, r = 0.51 and ****p < 0.0001in all breast cancer patients (4421), panel (A), r = 0.32 and ****p < 0.0001in ER-positive breast cancer patients (3685), panel (B), and r = 0.37 and ****p < 0.0001in ER-negative breast cancer patients (510), panel (C). Source: Database of The Breast Cancer Gene-Expression Miner v4.8 (bcGenExMiner v4.8) (http://bcgenex.ico.unicancer.fr/BC-GEM/GEM-Accueil.php?js=1) [56] Previous reports explained the good prognostic effect of PRLR expression in breast cancer's different subtypes. It is interesting to note that PRLR expression was discovered to be substantially downregulated in invasive breast cancer (21.4%) compared to in situ carcinoma (60%) and normal/benign (80%) (p = 0.003498). Furthermore, low-grade, well-differentiated tumours and lymph node negativity were linked to PRLR expression. The triple-negative breast cancer subtype, which has a worse prognosis, had almost no detectable PRLR expression. In contrast, the luminal A subtype- the least aggressive phenotype- had the highest PRLR expression (p = 0.00001) [43]. Together, these data indicate that both PRLR and ESR1 expression are clinically correlated and showed a highly interconnected role in breast cancer development and differentiation. PRLR/ER co-expression is associated with well-differentiated and low aggressivity luminal ER + breast cancer subtype Prolactin persuades its biological effects by stimulating the PRLR/JAK2/STAT5a/b signalling pathway [69, 112]. A strong connection was seen between the PRL pathway-based gene signature expression, which includes PRL, PRLR, JAK2, and STAT5a, and more differentiated tumours (p < 0.00001) [44]. Furthermore, a significant correlation (p < 0.00001) was perceived between the expression of a gene signature consisting of genes that were increased by PRL stimulation and the well-differentiated tumours. This demonstrates that the PRL hormone and its signalling pathway revealed a crucial rule for preserving tumour differentiation status and improving patient outcomes [44]. Moreover, the favourable predictive impact of PRLR expression in the various subtypes of breast cancer was clarified by earlier research showing a strong connection between PRLR expression and low-grade and well-differentiated tumours [43]. When it comes to ER expression, ER + breast cancer has unique clinicopathological characteristics, including older age, smaller size, lower grade, and a better prognosis [113, 114]. Similarly, it was discovered that well-differentiated breast carcinomas have higher levels of ER expression than poorly differentiated breast carcinomas [115]. Conversely, ER-low breast tumours were linked to increased Ki-67 expression, negative PR expression, positive HER2 expression, larger size, and higher histologic grade [113, 114]. Indeed, there was no discernible benefit from the ET for ER-low tumours, and they appeared to show higher recurrence rates than ER-high tumours [116]. According to these results, preserving a differentiated phenotype that demonstrated a positive response to ET therapy and positive patient outcomes requires the co-expression of these receptors, PRLR and ER. Our findings acknowledged the previous reports and confirmed that increased expression of ESR1 (ER-alpha) following PRL treatment resulted in a more differentiated phenotype and improved the response of the MCF-7 cells to the ET, inhibiting cancer cell viability. To further elucidate the prognostic power of these genes’ signature in correlation to different breast cancer molecular subtypes, ER status, and tumour grade/differentiation condition, we used the GOBO dataset that includes information about 1881 breast cancer patients [54, 55] to generate a gene set composed of PRLR and ESR1. As shown in Fig. 5A, B. Using both Hu and PAM50 classifications of breast tumours, our results disclosed a significant association between higher expression of PRLR-ESR1 genes signature in the least aggressive breast cancer subtype bestowing by Luminal A breast cancer subtype (p < 0.00001), HR + breast tumours (p < 0.00001), ER + tumours (Fig. 5C, p < 0.00001), and well-differentiated tumour grade (Fig. 5D, Grade 1, p < 0.00001). On the other hand, lower co-expression of PRLR-ESR1 genes signature was found in the most aggressive breast cancer subtype involving basal breast cancer (p < 0.00001), ER- tumours (p < 0.00001), and poorly differentiated tumour grade (Grade 3, p < 0.00001), Fig. 5A–D. Similar results were obtained when examining the co-expression of PRLR-ESR1 gene signature in breast cancer cell lines representative of different molecular subtypes. As can be seen in Fig. 5E, breast cancer cell lines demonstrative of the luminal (HR + /HER2−) subtype showed the highest expression profile of PRLR-ESR1 gene signature. In contrast, basal (A and B) and TNBC subtypes, which exhibit the most aggressive phenotype, revealed the lowest expression intensity. Collectively, these data should clarify the encouraging significance of the simultaneous expression of the PRLR and ESR1 genes in patients with breast cancer. This expression is associated with a well-differentiated phenotype and a lower degree of malignancy, both of which suggest the fruitful prognosis of these patients. Co-expression of PRLR/ESR1 strongly correlated with well-differed and less aggressive breast cancer subtypes: PRLR-ESR1 gene signature correlation expression level according to breast cancer molecular subtypes, Basal, HER2 + , Luminal A, Luminal B, Normal like, and Unclassified by both HU and PAM50 subtypes classifications showing significant correlation level in Luminal subtypes/ HR + , ****p < 0.0001, panels (A) & (B). PRLR-ESR1 gene signature correlation expression level according to ER status, ER- and ER + breast cancers, panel (C). Panel (D), PRLR-ESR1 gene signature expression level in correlation with histological grades G1, G2, and G3. PRLR-ESR1 genes signature exposed the highest expression profile in breast cancer cell lines that are representative of the luminal (HR + /HER2-) subtype, and the lowest expression intensity was determined in breast cancer cell lines that are representative of basal (A and B) and TNBC subtypes, panel (E). Source: Gene expression-based Outcome for Breast Cancer (GOBO) online database (http://co.bmc.lu.se/gobo/) [54, 55] PRLR/ER co-expression is associated with favourable breast cancer patient outcomes PRL pathway-based gene signature expression entailed PRL, PRLR, Jak2 and Stat5a was significantly correlated with prolonged RFS (p = 1.8 × 10–06) and OS (p = 0.0026) [44]. Additionally, Hachim et al. found that in breast cancer patients, the expression of PRLR was positively linked with prolonged DMFS and unveiled a significant association (p < 0.01) [43]. Likewise, the expression of ESR1 in ER + breast cancers was reported to be positively correlated with better patient outcomes [113, 114]. Indeed, ER-negative breast tumours showed higher recurrence and mortality rates as compared to ER + breast cancers [117]. Furthermore, patients with early ER + breast tumours were found to be superior to women with early ER-negative breast tumours by increasing the 5-year survival rate by 10 percent [118]. These studies implied that the expression of either the PRL signalling pathway or ESR1 in breast cancer patients exhibits promising patient prognosis and favourable sequelae. Therefore, next, we were interested in dissecting the influence of PRLR-ESR1 co-expression on breast cancer patient outcomes, using the KM plotter database [53] and calculating the mean expression values of both PRLR and ESR1 genes. As described in Fig. 6A, we found that higher mRNA co-expression levels of both PRLR and ESR1 are correlated with superior OS (p = 2.7–08), prolonged both RFS (p = 6.2–16) and DMFS (p = 5.4–09) in all subtypes of breast cancer patients. As per previous results, Fig. 5A–D demonstrated that the highest co-expression of PRLR-ESR1 gene signature was found in the HR + /Luminal A breast tumour subtypes. Next, we examined the effect of the co-expression of PRLR-ESR1 on patient outcomes in the Luminal A breast cancer subtypes using a similar dataset. Remarkably, co-expression levels of both PRLR and ESR1 are also correlated with favourable prognosis in Luminal A breast cancer patients presenting by better OS (p = 0.00049), RFS (p = 0.00013), and DMFS (p = 0.0024), Fig. 6B. This data validated the fruitful prognostic value of the parallel expression of PRLR and ESR1 genes in breast cancer patients harbouring more differentiated phenotypes. Co-expression of PRLR/ESR1 associated with favourable prognosis in patients breast cancer patients: PRLR-ESR1 gene signature is significantly associated with prolong OS (p = 2.7^−08), RFS (p = 6.2^−16), and DMFS (p = 5.4^−09), in all breast cancer subtypes, panel (A) and in Luminal A subtype, OS (p = 0.00049), RFS (p = 0.00013), and DMFS (p = 0.0024), panel (B). Source: The Kaplan–Meier Plotter, (https://kmplot.com/analysis/) [53] Conclusion Given our growing understanding of the roles played by tumour cellular plasticity in the development and evolution of cancer, considerable effort is being made to use differentiation pathways as a new cancer treatment avenue. The ultimate ambition of breast cancer management is to provide curative treatment that can control the disease’s recurrence and dissemination. This can be achieved by a fruitful response to conventional remedies by producing a homogenous cell population. The premise of differentiation therapy for cancer is to use cellular reprogramming and engage-forward differentiation to limit the proliferative, tumour repopulation, stemness, EMT, and metastatic capacities of tumour cells. This will stop the tumours from becoming aggressive and improve the reaction to targeted therapy and patients' chances of survival. Even though patients' therapy options for hormone receptor-positive tumours have significantly improved, including anti-estrogen-based therapies and others such as CDK4/6 inhibitors, for patients with TNBC, there are no other viable therapeutic choices available besides chemotherapy. Interestingly, none of these methods are therapies based on differentiation. To prevent aggressive malignant changes in the progression of tumours and to create new generation biomarkers and anti-cancer therapies based on the "forward-differentiation" model, it is imperative to identify the drivers and mechanisms of tumour cellular differentiation in breast cancer. Taking into consideration all the previous knowledge, the growing body of research on breast cancer suggests that PRL/PRLR is a clinically significant and influential differentiation pathway that restricts the tumorigenic phenotype and could, therefore, be a viable pro-differentiation therapy option. Moreover, as demonstrated by our study, combining standard and induction inducer agents would offer a less toxic approach than monotherapy. Ultimately, this work provides solid proof of the critical function of PRL in determining the differentiation of cancer cells and increasing their susceptibility to traditional therapy. Supplementary Information Supplementary material 1. Acknowledgements The author would like to acknowledge the Research Center for Health Sciences, Deanship of Graduate Studies and Scientific Research, Taif University, for supporting this project and extending her acknowledgment to the High-Altitude Research Center at Taif University. Author contributions A.S. planned the study and prepared all the logistics, conducted the Lab experiments, data analysis, interpretation of the results, generation of the figures, and final editing and drafting of the manuscript. Funding This research was funded by the Research Center for Health Sciences, Deanship of Graduate Studies and Scientific Research, Taif University, through project number (1-442-65). Data availability The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request. Declarations Ethics approval and consent to participate Not applicable. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary material 1. Data Availability Statement The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.